| Project/Area Number |
13557081
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
ORITANI Kenji Osaka University Graduate School of Medicine, Assistant Professor, 医学系研究科, 助手 (70324762)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KADOYA Toshihiko Kirin Brewery Co. LTD., Pharmaceutical Research Laboratory, Chief, 医薬探索研究所, 主任研究員
TOMIYAMA Yoshiaki Osaka University Graduate School of Medicine, Assistant Professor, 医学系研究科, 助手 (80252667)
岡島 裕 大阪大学, 医学部・附属病院, 医員
|
|---|
| Project Period (FY) |
2001 – 2002
|
| Project Status |
Completed (Fiscal Year 2002)
|
| Budget Amount *help |
¥13,900,000 (Direct Cost: ¥13,900,000)
Fiscal Year 2002: ¥5,400,000 (Direct Cost: ¥5,400,000)
Fiscal Year 2001: ¥8,500,000 (Direct Cost: ¥8,500,000)
|
|---|
| Keywords | Interferon / Limitin / anti-tumor / immunoregulatory / anti-viral / myelosuppression / gene expression / signals / limitin / Interferon / antivirus / bcr-abl / Tlymphocytes / perforin-granzyme |
|---|
| Research Abstract |
Limitin is an interferon (IFN)-like cytokine that has sequence homology with previously known type I IFNs and utilizes the IFN-α/β receptor for its biological activities. Using our established the anti-limitin antibody and recombinant limitin protein, we compared biological functions between limitin and IFN-α, and analyzed in vivo expression of limitin protein. (1) Limitin augmented the killer activity of cytotoxic T lymphocytes as well as the surface expression of MHC class I molecules. Limitin inhibited the proliferation of FDCP-1 cells stably transfected with p210bcr/abl. Limitin also induced antiviral state against EMCV, MHV, and HSV. Although the above functions of limitin were similar to those of IFN-α, higher concentration of limitin was required than IFN-α for the inhibition of CFU-IL7 or CFU-Meg colony formation. Limitin could not inhibit CFU-GM or BFU-E colony formation while IFN-α did. These data suggest that limitin may be less toxic than other IFNs, and therefore may have a unique
clinical niche for treatment of diseases where type I IFNs have proven useful. (2) Immunohistochemical analysis revealed that the limitin protein is produced by mature T lymphocytes in spleen and thymus in healthy mice. This result propose that cDNA from human thymus is a suitable source of cDNA library to screen human homolog of limitin. (3) The disruption of tyrosine kinase Tyk2 completely abrogated IFN-α-induced inhibition of CFU-IL7 and CFU-Meg colony formation as well as up-regulation and translocation of DAXX. These data indicate that Tyk2 plays an important role in IFN-mediated myelosuppression, and we are now analyzing the difference of signaling pathways between limitin and IFN-α.
|
